Country for PR: United States
Contributor: PR Newswire New York
Friday, November 20 2020 - 03:53
MIM Software Inc. Announces Collaboration with Peter MacCallum Cancer Centre to Improve Patient Management
CLEVELAND, Nov. 20, 2020 /PRNewswire-AsiaNet/ --

MIM Software Inc., a leading global provider of medical imaging software, 
announced today a collaboration with Peter MacCallum Cancer Centre (Peter Mac) 
in support of its Prostate Cancer Theranostics and Imaging Centre of Excellence 
(ProsTIC) program.

Logo -

Peter Mac and MIM Software will collaborate to improve prostate cancer patient 
management through the program. ProsTIC will develop tools that aid clinicians 
in oncologic cancer staging, treatment planning, therapy response assessment, 
and recurrence detection.

Peter Mac introduced the ProsTIC program to expand clinical trial research, 
establish an educational hub on the benefits of new technology, and conduct 
further research on next-generation targets.

"The Prostate Cancer Theranostics and Imaging Centre of Excellence at Peter 
MacCallum Cancer Centre in Melbourne is proud to collaborate with MIM Software 
to enhance our program," said Professor Michael Hofman, Nuclear Medicine 
physician, and physician-scientist at Peter Mac. "Clinical researchers will 
collaborate with MIM Software to perform advanced analysis of PET images and 
develop new methods for whole-body tumor analysis. We hope to identify new 
prognostic or predictive imaging biomarkers and also contribute to the 
development of artificial intelligence algorithms that will improve patient 
outcomes through improved, personalized medicine."

PET/CT imaging is an essential tool for disease identification. However, the 
process of differentiating a tumor from normal uptake on oncologic PET/CT scans 
is time-consuming. There is also an immense amount of quantitative data in 
these exams not currently captured and potentially important for determining a 
patient's prognosis. The collection of this data will result in more 
personalized patient care, including treatment response assessment.

"There is a demand for more quantitation to increase clinician confidence, and 
MIM Software can play a significant role in helping to predict patient outcomes 
as a result of data-driven decision-making," said Aaron Nelson, MD, Chief 
Medical Officer of MIM Software Inc. "This collaboration with Peter MacCallum 
Cancer Centre will help develop a reproducible and efficient method for 
quantification of FDG and Ga-68 PSMA PET lesions."

About MIM Software Inc.
MIM Software is committed to enhancing patient care by providing 
customer-focused and innovative imaging, workflow, and data solutions. MIM 
Software offers a central software package that allows industry-leading 
oncology tools to be utilized together to ensure plan quality and maximize 
effective data usage and efficiency. 

Headquartered in Cleveland, OH, MIM Software is a privately held company with 
offices worldwide.

To learn more about MIM Software, visit

About The Peter MacCallum Cancer Centre
Peter MacCallum Cancer Centre is a world-leading cancer research, education, 
and treatment center, and Australia's only public health service solely 
dedicated to caring for people affected by cancer.

The hospital has over 3,200 staff, including more than 700 laboratory and 
clinical researchers, all focused on providing better treatments, better care, 
and potential cures for cancer.

To learn more about Peter Mac and the ProsTIC program, visit 

CONTACT: Nicholas Sewell, Senior Public Relations & Marketing Specialist, 

SOURCE: MIM Software Inc.